The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback